文献速递胸部肿瘤

PD-1/PD-L1复合物的功能性结合而非PD-L1表达高度预测非小细胞肺癌患者对免疫治疗的应答

Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2023-02-23

研究使用高通量自动化定量成像平台(QF-Pro)在188例免疫检查点抑制剂治疗的非小细胞肺癌患者肿瘤样本中量化细胞间PD-1/PD-L1相互作用。多中心盲法分析显示PD-1/PD-L1结合程度与PD-L1表达无相关性,临床用于分层的PD-L1表达评分与总生存相关性差,而高PD-1/PD-L1相互作用患者对抗PD-1/PD-L1治疗应答显著更好(总生存增加),一线治疗中尤为明显。

要点

  • PD-1/PD-L1相互作用程度与PD-L1表达无相关性。
  • 临床PD-L1表达评分与总生存相关性差。
  • 高PD-1/PD-L1相互作用患者总生存显著改善,一线治疗中尤强。

核心结论

  • PD-1/PD-L1相互作用的功能性读数作为预测性生物标志物联合PD-L1表达应能显著提高非小细胞肺癌患者免疫治疗应答率。
  • 该策略可捕获被排除于检查点免疫治疗之外的患者(高PD-1/PD-L1相互作用但低PD-L1表达,占24%)。
  • 该策略还可避免治疗那些尽管高PD-L1表达但无应答且遭受副作用的患者。

研究设计与样本

  • 多中心盲法分析,纳入188例接受免疫检查点抑制剂治疗的非小细胞肺癌患者。
  • 使用高通量自动化定量成像平台(定量功能蛋白质组学,QF-Pro)在福尔马林固定石蜡包埋肿瘤样本中量化细胞间PD-1/PD-L1相互作用。

主要发现

  • 多中心盲法分析显示PD-1/PD-L1免疫检查点结合存在瘤内和瘤间异质性,且PD-1/PD-L1相互作用程度与PD-L1表达无相关性。
  • 临床用于患者分层的PD-L1表达评分与总生存相关性差。
  • 高PD-1/PD-L1相互作用患者对抗PD-1/PD-L1治疗应答显著更好,表现为总生存增加。
  • 该关系在一线治疗中尤为强。

关键数值与推荐

  • 高PD-1/PD-L1相互作用但低PD-L1表达的患者占24%。

临床怎么用

  • 作者认为PD-1/PD-L1相互作用的功能性读数联合PD-L1表达用于非小细胞肺癌患者分层应能显著提高免疫治疗应答率。
  • 作者认为该策略可捕获高PD-1/PD-L1相互作用但低PD-L1表达(24%)而被排除于检查点免疫治疗之外的患者。
  • 作者认为该策略可避免治疗尽管高PD-L1表达但无应答且遭受副作用的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In many cancers, the expression of immunomodulatory ligands leads to immunoevasion, as exemplified by the interaction of PD-L1 with PD-1 on tumor-infiltrating lymphocytes. Profound advances in cancer treatments have come with the advent of immunotherapies directed at blocking these immuno-suppressive ligand-receptor interactions. However, although there has been success in the use of these immune checkpoint interventions, correct patient stratification for these therapies has been challenging. MATERIALS AND METHODS: To address this issue of patient stratification, we have quantified the intercellular PD-1/PD-L1 interaction in formalin-fixed paraffin-embedded tumor samples from patients with non-small cell lung carcinoma, using a high-throughput automated quantitative imaging platform (quantitative functional proteomics [QF-Pro]). RESULTS: The multisite blinded analysis across a cohort of 188 immune checkpoint inhibitor-treated patients demonstrated the intra- and intertumoral heterogeneity of PD-1/PD-L1 immune checkpoint engagement and notably showed no correlation between the extent of PD-1/PD-L1 interaction and PD-L1 expression. Importantly, PD-L1 expression scores used clinically to stratify patients correlated poorly with overall survival; by contrast, patients showing a high PD-1/PD-L1 interaction had significantly better responses to anti-PD-1/PD-L1 treatments, as evidenced by increased overall survival. This relationship was particularly strong in the setting of first-line treatments. CONCLUSION: The functional readout of PD-1/PD-L1 interaction as a predictive biomarker for the stratification of patients with non-small-cell lung carcinoma, combined with PD-L1 expression, should significantly improve the response rates to immunotherapy. This would both capture patients excluded from checkpoint immunotherapy (high PD-1/PD-L1 interaction but low PD-L1 expression, 24% of patients) and additionally avoid treating patients who despite their high PD-L1 expression do not respond and suffer from side effects.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sánchez-Magraner L, Gumuzio J, Miles J, et al. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 36821809. doi:10.1200/JCO.22.01748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。